A number of research firms have changed their ratings and price targets for Kiniksa Pharmaceuticals International (NASDAQ: KNSA):
- 10/30/2026 – Kiniksa Pharmaceuticals International had its price target raised by JPMorgan Chase & Co. from $107.00 to $122.00. They now have an “overweight” rating on the stock.
- 10/28/2026 – Kiniksa Pharmaceuticals International was downgraded by Weiss Ratings from “buy (b-)” to “hold (c-)”.
- 10/28/2026 – Kiniksa Pharmaceuticals International had its price target raised by The Goldman Sachs Group from $90.00 to $101.00. They now have a “buy” rating on the stock.
- 10/28/2026 – Kiniksa Pharmaceuticals International had its price target raised by Wedbush from $99.00 to $102.00. They now have an “outperform” rating on the stock.
- 10/28/2026 – Kiniksa Pharmaceuticals International had its price target raised by Wells Fargo & Company from $87.00 to $110.00. They now have an “overweight” rating on the stock.
- 10/8/2026 – Kiniksa Pharmaceuticals International was upgraded by Weiss Ratings from “hold (c+)” to “buy (b-)”.
- 9/30/2026 – Kiniksa Pharmaceuticals International is now covered by Wells Fargo & Company. They set an “overweight” rating and a $87.00 price target on the stock.
Kiniksa Pharmaceuticals International Stock Down 0.9%
KNSA stock traded down $0.85 during midday trading on Monday, reaching $95.47. The company’s stock had a trading volume of 115,173 shares, compared to its average volume of 701,583. Kiniksa Pharmaceuticals International, plc has a 52 week low of $37.02 and a 52 week high of $99.31. The stock has a market cap of $7.50 billion, a PE ratio of 73.44 and a beta of 0.07. The business’s 50-day simple moving average is $82.18 and its 200-day simple moving average is $62.70.
Kiniksa Pharmaceuticals International (NASDAQ:KNSA – Get Free Report) last posted its quarterly earnings results on Tuesday, October 27th. The company reported $0.56 earnings per share for the quarter, beating analysts’ consensus estimates of $0.37 by $0.19. Kiniksa Pharmaceuticals International had a return on equity of 17.27% and a net margin of 11.58%. The company had revenue of $285.97 million for the quarter, compared to the consensus estimate of $260.66 million. As a group, equities analysts forecast that Kiniksa Pharmaceuticals International, plc will post 1.30 earnings per share for the current fiscal year.
Insider Activity
Kiniksa Pharmaceuticals International plc is a biopharmaceutical company focused on developing and commercializing treatments for patients with autoimmune and inflammatory diseases. The company was established in 2015 and has operations in the United States and internationally. Kiniksa’s marketed medicine, Arcalyst (rilonacept), is approved in the United States to treat recurrent pericarditis and reduce the risk of recurrence in adults and certain pediatric patients. It is also approved for cryopyrin-associated periodic syndromes, a group of rare autoinflammatory conditions.
Read More
- Five stocks we like better than Kiniksa Pharmaceuticals International
- Orbiting Growth: Federal Contracts Boost Viasat’s Outlook
- Modine Manufacturing Scales Up to Solve the AI Heat Problem
- Nebius Revenue Is Surging, But Its Spending Is Raising Bigger Questions
- Embraer’s Record Backlog Looks Promising, But Can It Keep Its Margins Climbing?
Receive News & Ratings for Kiniksa Pharmaceuticals International plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kiniksa Pharmaceuticals International plc and related companies with MarketBeat.com's FREE daily email newsletter.
